Clinical trial · Interventional
Rosiglitazone in Treating Patients With Liposarcoma
Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma
NCT00004180CI-TRIAL-00067508completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rosiglitazone maleate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Well-differentiated liposarcoma
- description
- Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
- interventionNames
- Drug: rosiglitazone maleate
- type
- EXPERIMENTAL
- label
- De-differentiated liposarcoma
- description
- Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
- interventionNames
- Drug: rosiglitazone maleate
- type
- EXPERIMENTAL
- label
- Myxoid/ round-cell liposarcoma
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven liposarcoma that is incurable with standard multimodality approaches (e.g., surgery and/or radiotherapy and/or chemotherapy) * Well differentiated OR * Dedifferentiated OR * Myxoid/round cell OR * Pleomorphic * Measurable disease * No clinically unstable brain metastases * No progression on prior troglitazone therapy for liposarcoma PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 3 months Hematopoietic: * Absolute neutrophil count at least 1,000/mm3 * Platelet count at least 90,000/mm3 Hepatic: * Bilirubin no greater than 2.0 mg/dL * SGOT less than 5 times upper limit of normal Renal: * Creatinine no greater than 2.4 mg/dL Cardiovascular: * No poorly controlled atrial arrhythmias, symptomatic angina pectoris, or myocardial infarction within the past 4 months * No symptomatic congestive heart failure, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within the past 3 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception * Oral contraceptives are not considered effective contraception * No active retroviral disease * No condition that would preclude informed consent PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics * Prior chemotherapy allowed and recovered * No concurrent cytotoxic therapy Endocrine therapy: * No concurrent hormonal therapy Radiotherapy: * See Disease Characteristics * Prior radiotherapy allowed and recovered * At least 6 months since prior radiotherapy to the sole site of measurable disease * Concurrent localized radiotherapy to a single site of disease allowed if there are other sites of measurable disease Surgery: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.